InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate in Upcoming H.C. Wainwright Annual Global Investment Conference
July 26, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is scheduled for Sept. 9–11, 2024, and will be held both virtually and in person in New York City. According […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters into $2.1M Registered Direct Offering
July 19, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into definitive agreements for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per unit in a registered direct offering priced at-the-market under Nasdaq […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Device and CMC Development Master Plan to Support IND-Enabling Study of SPC-15
July 18, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into a Device and CMC Development Master Plan with medical technology provider Resyca BV. A joint venture between Bespak Group and Medspray Pharma BV, Resyca manufactures the formulation-specific microchip-based spray system […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Exclusive Global License to Develop, Manufacture, Commercialize Alzheimer Drug
July 16, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into an exclusive global license agreement. The agreement outlines the company’s intentions to further develop, manufacture and commercialize SPC-14, SILO’s Alzheimer’s drug. According to the announcement, the company plans to follow […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters License Agreement with Columbia University for Lead Candidate Targeting PTSD, Stress-Induced Anxiety Disorders
July 8, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into a license agreement with Columbia University. The agreement, which is exclusive and global, outlines plans to further develop, manufacture and commercialize Silo’s lead drug candidate, SPC-15. According to the announcement, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Sees “Swell” of Insider Investments, Upgrade in Ranking after Positive Year-End Report
July 8, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases following the company’s year-end update; the report highlighted significant advancements that strengthened Cybin’s position in the development of next-generation psychedelic-based therapeutics. […]
InvestorNewsBreaks – Laredo Oil Inc. (LRDC), Subsidiary Announce Oil Shows as Drilling Depth Met at First of Three Midfork Production Wells
July 5, 2024
Laredo Oil (OTC: LRDC), an oil exploration and production company, and its wholly owned subsidiary, Hell Creek Crude (“HCC”) LLC, are reporting oil shows in three zones of the Reddig 11-21 well in the Midfork field located in Valley County, Montana. The oil shows were discovered as total drilling depth was met in drilling operated by […]
InvestorNewsBreaks — Laredo Oil Inc. (LRDC) Subisidary Begins Drilling on Well in Montana-Based Midfork Location
June 28, 2024
Laredo Oil (OTC: LRDC),an oil exploration and production company, and its wholly owned subsidiary, Hell Creek Crude LLC, have started drilling the Reddig 11-21 well in the Midfork field located in Valley County, Montana. According to the announcement, the well is the first of three production wells that the company, which operates in the Midfork field, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases FY Financial Report, Business Update
June 26, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting its audited financial results for the fiscal year ended March 31, 2024; the report also included a business overview. Highlights of the report include the company […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Collaborates with CRO Partner to Advance SPC-15 for PTSD
June 26, 2024
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced that it has awarded a contract to its contract research organization (“CRO”) partner AmplifyBio for an investigational new drug (“IND”)-enabling large animal GLP (Good Laboratory Practice) […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Featured Presenter at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference
June 20, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be spotlighted during an upcoming online fireside chat at the H.C. Wainwright Fifth Annual Neuro Perspectives Virtual Conference. According to the announcement, Cybin CEO Doug Drysdale will present during […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Strategic Appointment of Dr. Atul Mahableshwarkar
June 11, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company today announced its appointment of Dr. Atul R. Mahableshwarkar M.D., DLFAPA, as its senior vice president, clinical development. Dr. Mahableshwarkar will lead the development of the CYB003 […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes on $2M Registered Direct Offering, Provides Update on SP-26 Ketamine Implant Therapeutic
June 7, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has closed on a previously announced registered direct offering. According to the announcement, the offering was comprised of 917,432 shares of common stock (or common stock equivalents in lieu thereof) offered at a […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Registered Direct Offering Estimated to Reach $2M
June 5, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into definitive agreements for the purchase and sale of common stock. Specifically, the agreements are for a registered direct offering of 917,432 shares of common stock for $2.18 per share. In […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Pre-IND Submission for Proprietary Treatment for PTSD, Anxiety
June 4, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has submitted a pre-Investigational New Drug (“pre-IND”) briefing package and meeting request to the U.S. Food and Drug Administration (“FDA”). The submission is for Silo Pharma’s intranasal prophylactic treatment for post-traumatic stress disorder […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at Interdisciplinary Conference on Psychedelic Research 2024
May 29, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company today announced that its Chief Medical Officer Amir Inamdar, MBBS, DNB (Psych), MFPM and Director, Clinical Development Ellen James, Ph.D. will participate at the Interdisciplinary Conference on […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares ‘Significant Development’ in Depression Study Showing Potential to Extend Remission Period, Prevent Relapse
May 21, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, is reporting on results from a study that has identified a potential new drug formulation that could extend the remission period and prevent relapse in individuals dealing with depression. According to the announcement, […]
Bebuzee Inc. (BBUZ) Looks to Challenge the Status Quo in the US and European Tech Ecosystems with the Launch of the Bebuzee Super App
May 15, 2024
Today, the common practice for companies in the American digital landscape is to create multiple applications and websites that offer customers only a fraction of the functionalities found in the super apps dominating the Asian tech ecosystem. The distributed nature of these functionalities across different platforms has long meant that services such as communication, entertainment, […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Participation in FDA Event Exploring Emerging Therapeutic Interest in Ketamine
May 14, 2024
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its planned attendance at a hybrid public meeting on June 27, 2024. The meeting will be hosted by the U.S. Food and Drug Administration (“FDA”) in partnership with the […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Slated to Present at Upcoming Alliance Global Partners Healthcare Company Showcase
May 14, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be participating in an upcoming virtual Alliance Global Partners Healthcare Company Showcase. The event is scheduled for May 21, 2024. According to the announcement, Cybin CEO Doug Drysdale will […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Issues Corporate Update, Eyes Runway for Upcoming Clinical Milestones
May 6, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company has provided a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline. “With the prevalence and burden of mental health conditions at […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference
April 25, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at the Beverly Hilton in Los Angeles. According to the announcement, Doug Drysdale, Cybin CEO, will appear […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Update on Plan of Arrangement with Exopharm Limited
April 24, 2024
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved a previously announced plan of arrangement between Exopharm Limited and Tryp (the “parties”). The announcement confirmed […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares Positive Results for PTSD Treatment
April 23, 2024
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced positive data in the final validation report from the recent pharmacokinetic (“PK”) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (“PTSD”). […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Research Published in “Journal of Medicinal Chemistry”
April 18, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting that its research has been published in a prestigious biweekly, peer-reviewed publication. Titled “Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Notice of Patent Grant for CYB003 Breakthrough MDD Therapy Program
April 16, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, has received notification that the United States Patent and Trademark Office has granted a patent in support of its CYB003 program in Major Depressive Disorder (“MDD”). The patent covers claims […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Plans for Exclusive Licensing of Novel Therapeutic for Alzheimer’s Disease
April 10, 2024
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, is exercising its option to license Alzheimer’s disease (“AD”) therapeutic SPC-14 from Columbia University. The option was outlined in a research and option agreement between Silo Pharma and the university in 2021. According […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Bloom Burton & Co. Healthcare Conference
April 10, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, announced that its CEO Doug Drysdale will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference. The event is slated to take place April 16-17 in Toronto, Ontario. […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Exercises Option for Exclusive License Agreement for SPC-15
March 20, 2024
Silo Pharma (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced that it has exercised its option to license SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD, from Columbia University, pursuant to a sponsored […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming Public Ventures Discovery Day
March 18, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be presenting at this week’s Public Ventures Discovery Day. The event is scheduled for March 19, 2024, in Dallas. During the event, Cybin CEO Doug Drysdale will participate in […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Groundbreaking Ketamine Implant Therapeutic
March 18, 2024
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its filing of a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent and Trademark Office (“USPTO”). The patent application includes protection for Silo […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Initiates Phase 2 Study of CYB004 for Generalized Anxiety Disorder
March 15, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is reporting the initiation of a Phase 2 proof-of-concept study of CYB004, its proprietary deuterated dimethyltryptamine (“DMT”) molecule in development for the treatment of generalized anxiety disorder (“GAD”). The randomized, […]
InvestorNewsBreaks — Laredo Oil Inc. (LRDC) Reports That Texakoma Is Exercising Option to Drill Valley County Wells
March 14, 2024
Laredo Oil (OTC: LRDC), an oil exploration and production company, announced that Texakoma Exploration and Production LLC (“Texakoma”) has exercised its option to drill the next eight wells under its agreement with Laredo Oil’s wholly-owned subsidiary, Lustre Oil Company LLC, and Erehwon Oil & Gas, LLC. The agreement also includes participation in the development of […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Meeting with FDA to Review End of Phase 2 Study, Proposed Phase 3 Program
March 14, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting on its end-of-phase-2 meeting with the U.S. Food and Drug Administration (“FDA”). The meeting was regarding CYB003, the company’s deuterated psilocybin analog for the adjunctive treatment of major […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives Share CYB003 Program Update During Webcast
March 13, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, hosted a conference call and webcast this morning at 8:30 a.m. ET. According to the announcement, the company provided an update on CYB003, its proprietary deuterated psilocybin analog being developed […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Shareholders Approve Arrangement Agreement at Annual General and Special Meeting
March 13, 2024
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that company shareholders approved an announced arrangement involving the company and Exopharm Limited CAN 163 765 991. Tryp securityholders approved the arrangement during the company’s annual […]
InvestorNewsBreaks — Laredo Oil Inc. (LRDC) Subsidiary Reaches Agreement to Settle Mineral Rights Litigation
March 11, 2024
Laredo Oil (OTC: LRDC), an oil exploration and production company, through its wholly owned subsidiary Lustre Oil Company LLC, has announced an agreement to settle litigation. According to the announcement, the company has entered “a mutually agreeable settlement agreement between Lustre, Erehwon Oil & Gas LLC and A&S Minerals Development Company (‘ASMD’) LLC.” The agreement, which […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Completes Successful Dose-Ranging Study in Advancement of SPC-15
February 28, 2024
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced positive results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (“PTSD”). The purpose of the study […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming TD Cowen Health Care Conference
February 27, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be spotlighted at next month’s 44th annual TD Cowen Health Care Conference. The three-day event is scheduled for March 4–6, 2024, in Boston. During the conference, Cybin CEO Doug Drysdale […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Validation of Delivery System for SP-26
February 14, 2024
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. According to the announcement, a pre-clinical research study is underway […]